HIV-1 entry inhibition by small-molecule CCR5 antagonists: A combined molecular modeling and mutant study using a high-throughput assay

Journal Article · Tue May 10 00:00:00 EDT 2011 · Virology

DOI:https://doi.org/10.1016/j.virol.2011.02.016· OSTI ID:21486936

Labrecque, Jean ^[1]; Metz, Markus ^[2]; Lau, Gloria; Darkes, Marilyn C; Wong, Rebecca S.Y. ^[1]; Bogucki, David; Carpenter, Bryon; Gang, Chen; Tongshuang, Li; Nan, Susan ^[2]; Schols, Dominique ^[3]; Bridger, Gary J ^[2]; Fricker, Simon P ^[1]

---

1. Department of Biology, AnorMED Inc. now Genzyme Corporation, 500 Kendall Street, Cambridge, MA 02142 (United States)
2. Department of Chemistry, AnorMED Inc. now Genzyme Corporation, 500 Kendall Street, Cambridge, MA 02142 (United States)
3. Rega Institute for Medical Research, Katholieke Universiteit Leuven, Minderbroedersstraat 10, B-3000, Leuven (Belgium)

Based on the attrition rate of CCR5 small molecule antagonists in the clinic the discovery and development of next generation antagonists with an improved pharmacology and safety profile is necessary. Herein, we describe a combined molecular modeling, CCR5-mediated cell fusion, and receptor site-directed mutagenesis approach to study the molecular interactions of six structurally diverse compounds (aplaviroc, maraviroc, vicriviroc, TAK-779, SCH-C and a benzyloxycarbonyl-aminopiperidin-1-yl-butane derivative) with CCR5, a coreceptor for CCR5-tropic HIV-1 strains. This is the first study using an antifusogenic assay, a model of the interaction of the gp120 envelope protein with CCR5. This assay avoids the use of radioactivity and HIV infection assays, and can be used in a high throughput mode. The assay was validated by comparison with other established CCR5 assays. Given the hydrophobic nature of the binding pocket several binding models are suggested which could prove useful in the rational drug design of new lead compounds.

• OSTI ID: 21486936
• Journal Information: Virology, Vol. 413, Issue 2; Other Information: DOI: 10.1016/j.virol.2011.02.016; PII: S0042-6822(11)00088-2; Copyright (c) 2011 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.; ISSN 0042-6822
• Country of Publication: United States
• Language: English

Related Subjects

60 APPLIED LIFE SCIENCES
AIDS VIRUS
INHIBITION
INTERACTIONS
MUTAGENESIS
MUTANTS
PROTEINS
RECEPTORS
SIMULATION
STRAINS
MEMBRANE PROTEINS
MICROORGANISMS
ORGANIC COMPOUNDS
PARASITES
VIRUSES